ID
11638
Description
Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel for up to a Year in Scalp Psoriasis ODM derived from http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Link
http://clinicaltrials.gov/ct2/show/NCT00148213?term=NCT00148213&rank=1
Keywords
Versions (2)
- 11/24/11 11/24/11 -
- 7/9/15 7/9/15 - Martin Dugas
Uploaded on
July 9, 2015
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Psoriasis NCT00216879
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI-1
- C0680251
Description
PUVA or Grenz ray therapy anywhere on the patient within 28 days prior to randomisation
Data type
boolean
Alias
- UMLS CUI-1
- C0853073
- UMLS CUI-2
- C0018233
Description
UVB therapy anywhere on the patient within 14 days prior to randomisation
Data type
boolean
Alias
- UMLS CUI-1
- C0564461
Description
Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on, scalp psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab) within 6 months prior to randomisaiton
Data type
boolean
Alias
- UMLS CUI-1
- C0005522
Description
Systemic treatments with a potential effect on scalp psoriasis vulgaris (e.g., corticosteroids, retinoids, immunosuppressants) within 28 days prior to randomisation
Data type
boolean
Alias
- UMLS CUI-1
- C1515119
Description
Any topical treatment for scalp psoriasis or any other skin disease on the scalp (excluding medicated shampoos, emollients and hair conditioners) within 14 days prior to randomisaiton
Data type
boolean
Alias
- UMLS CUI-1
- C0150349
Description
Topical treatment for other skin disorders with very potent WHO group IV corticosteroids within 14 days prior to randomisation
Data type
boolean
Alias
- UMLS CUI-1
- C0150349
- UMLS CUI-2
- C0001617
Description
Planned initiation of, or changes in dose of concomitant medication that could affect scalp psoriasis (e.g., beta blockers, antimalarial drugs, lithium) during the study
Data type
boolean
Alias
- UMLS CUI-1
- C2347852
Description
Current diagnosis of guttate, pustular, exfoliative or erythrodermic psoriasis
Data type
boolean
Alias
- UMLS CUI-1
- C0343052
- UMLS CUI-2
- C0152081
- UMLS CUI-3
- C0748052
Description
Patients with any of the following conditions present on the scalp area: viral lesions, fungal and bacterial skin infections, parasitic infections and atrophic skin
Data type
boolean
Alias
- UMLS CUI-1
- C0037278
Description
Known or suspected severe renal insufficiency or severe hepatic disorders
Data type
boolean
Alias
- UMLS CUI-1
- C1565489
- UMLS CUI-2
- C1869009
Description
Patiens with history/signs/symptoms suggestive of an abnormality of calcium homeostasis associated with clinically significant hypercalcaemia
Data type
boolean
Alias
- UMLS CUI-1
- C0020437
Description
Trial subjects should be using an adequate method of contraception
Data type
boolean
Alias
- UMLS CUI-1
- C0700589
Similar models
Eligibility Psoriasis NCT00216879
- StudyEvent: Eligibility
C0018233 (UMLS CUI-2)
C0001617 (UMLS CUI-2)
C0152081 (UMLS CUI-2)
C0748052 (UMLS CUI-3)
C1869009 (UMLS CUI-2)